dapivirine ring

  • Meeting Report: Stakeholder Consultation on MTN–042

    The Microbicide Trials Network (MTN), in partnership with AVAC, held a consultation with key stakeholders in Johannesburg, South Africa, from April 5–6, 2018, to hear their views about the design and objectives of the MTN–042 study and to seek their opinions about specific aspects of the study. Held as part of the protocol development process, the consultation was timed so that stakeholder feedback could then be considered at a meeting of the team developing the MTN–042 study protocol.

  • The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding

    Knowing whether daily oral pre-exposure prophylaxis (PrEP) and use of the monthly dapivirine ring are safe during pregnancy and breastfeeding is vitally important. This fact sheet provides background on two studies that will address these questions.

  • MTN–042 – DELIVER

    Links are provided to information about the DELIVER study, which is evaluating the safety and acceptability of the use of a monthly dapivirine ring or a daily antiretroviral pill (FTC/TDF, or Truvada) during pregnancy.

  • REACH Study (MTN–034)

    Links are provided to information about Reversing the Epidemic in Africa with Choices in HIV prevention (REACH), or MTN-034, a trial evaluating how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP). The Microbicide Trials Network is conducting this trial to gain a better understanding of the HIV prevention needs and preferences of adolescent girls and young women and to collect information on the safety of both approaches for women in these age groups.

  • REACH HIV Prevention Study in Africa (Video)

    Aimed at potential study participants, this video provides background and describes the purpose and design of the Reversing the Epidemic in Africa with Choices in HIV prevention (REACH) study, or MTN-034. REACH is an open-label trial to evaluate how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP).

  • After The Ring Study: DREAM

    A fact sheet about DREAM (Dapivirine Ring Extended Access and Monitoring), an open-label extension study that provided monthly dapivirine rings for one year to women who had participated in The Ring Study, provides information on the purpose, design, and results of the study.

  • MTN–025 – HOPE

    Links are provided to information about the results and background of the HIV Open Label Prevention (HOPE) trial, a follow-on to the ASPIRE trial in which former ASPIRE participants were offered the opportunity to use the dapivirine ring in the context of a study. MTN conducted this trial to gather additional information on the ring’s safety, how women use the ring knowing that it can help reduce their risk of HIV, and the relationship between adherence and HIV protection.

  • Dapivirine Ring: The Case for Action

    This report examines the need for the the dapivirine monthly ring, its potential contribution to HIV prevention, and the steps that must be taken while the product is clearing initial regulatory approvals to ensure speedy access for women and girls.

  • Dapivirine Ring Modeling Literature Review

    The aim of this literature review is to identify the scope of completed dapivirine ring and microbicide modeling to date, to inform modeling work that the OPTIONS Consortium intends to undertake in 2017. A bibliography is available at: http://www.prepwatch.org/mpii-tools-resources/.

  • A Review of Social and Behavioral Factors Influencing Dapivirine Ring Use

    The purpose of this literature review is to provide a comprehensive overview of social and behavioral findings from dapivirine ring studies, to inform an investment case for the dapivirine ring and guide further research to prepare for uptake. Most completed studies addressed acceptability and adherence, but the review also examines factors such as partner buy-in, product preferences, and ring delivery. A bibliography is available at: http://www.prepwatch.org/mpii-tools-resources/.

Pages